Gilead Sciences (GILD) EBITDA Margin (QoQ) (2009 - 2026)

Gilead Sciences (GILD) EBITDA Margin (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 1,212.00
Dec 31, 2025 -1,779.00
Sep 30, 2025 789.00
Jun 30, 2025 138.00
Mar 31, 2025 116.00
Dec 31, 2024 2,063.00
Sep 30, 2024 -2,625.00
Jun 30, 2024 10,266.00
Mar 31, 2024 -8,730.00
Dec 31, 2023 -1,454.00
Sep 30, 2023 1,197.00
Jun 30, 2023 -161.00
Mar 31, 2023 -384.00
Dec 31, 2022 -961.00
Sep 30, 2022 787.00
Jun 30, 2022 2,942.00
Mar 31, 2022 -999.00
Dec 31, 2021 -3,880.00
Sep 30, 2021 1,565.00
Jun 30, 2021 -887.00